ABEO - NASDAQ
Abeona Therapeutics Inc.
$5.89
+3.6%Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
At a Glance
Live SnapshotAbeona Therapeutics Inc. Management Team
Mr. Joseph Walter Vazzano CPA
Chief Financial Officer
Compensation
$889,039
Dr. Brendan M. O'Malley J.D., Ph.D.
Chief Legal Officer
Compensation
$777,529
Ms. Alison Hardgrove
Chief People Officer
Dr. Vishwas Seshadri M.B.A., Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,471,508
Mr. Carl Denny
Senior Vice President of Regulatory Affairs
Dr. Madhav Vasanthavada M.B.A., Ph.D.
Senior Vice President, Chief Commercial Officer & Head of Business Development
Mr. Brian Kevany Ph.D.
Senior Vice President, Chief Technology Officer & CSO
Mr. Jon Voss
Vice President & Head of Quality
Mr. Gregory Gin
Vice President of Investor Relations & Corporate Communications
Abeona Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have sold $3.53M worth of ABEO shares, with no buying activity reported.
3 Months
0
0.00
69.0K
348.39K
-348K
-$348K
3-6 Months
0
0.00
224.4K
1.18M
-1.2M
-$1.18M
6-9 Months
0
0.00
78.6K
410.39K
-410K
-$410K
9-12 Months
0
0.00
254.5K
1.59M
-1.6M
-$1.59M
Top Buyers
No buying activity
Top Sellers
Seshadri Vishwas
Director, Officer: Chief Executive Officer
$1.62M
Vazzano Joseph Walter
Officer: Chief Financial Officer
$541K
O'Malley Brendan M.
Officer: Svp, Chief Legal Officer
$299K
Alvino Mark
Director
$264K
Crombez Eric
Director
$260K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $3.53M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
ABEO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 09, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | November 12, 2024 | November 12, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | March 19, 2024 | March 19, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 13, 2023 | April 13, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | July 11, 2022 | August 17, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | May 12, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 09, 2021 | May 26, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 10, 2020 | May 20, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 11, 2019 | May 28, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.